1. | | Recruiting | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Condition: Carcinoma, Adrenal Cortical |
2. | | Recruiting | Study of the Anti-angiogenesis Agent AG-013736 in Patients with Metastatic Thyroid Cancer Conditions: Thyroid Cancer; Metastases |
3. | | Recruiting | CCI-779 in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Conditions: gastrointestinal carcinoid tumor; Islet Cell Carcinoma; pulmonary carcinoid tumor |
4. | | Not yet recruiting | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
5. | | Recruiting | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Treating Patients With Recurrent Late-Stage Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer |
6. | | Recruiting | Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer Conditions: stage I ovarian epithelial cancer; stage II ovarian epithelial cancer; stage III ovarian epithelial cancer; peritoneal cavity cancer |
7. | | Recruiting | FR901228 in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
8. | | Recruiting | Second-Line Treatment for Patients with Platinum-Sensitive Ovarian Cancer Condition: Ovarian Cancer |
9. | | Not yet recruiting | Acupuncture for Women's Health Conditions Conditions: Ovarian Neoplasms; Endometriosis; Pelvic Pain; Uterine Neoplasms |
10. | | Recruiting | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal Cancer Conditions: Endocrine Cancer; female reproductive cancer; Gastrointestinal Cancer; musculoskeletal cancer; unclassified and other cancer |
11. | | Recruiting | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
12. | | Recruiting | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
13. | | Recruiting | Study of Ovarex® (oregovomab) MAb with Front-line Chemotherapy for Ovarian Cancer Treatment Condition: Ovarian Cancer |
14. | | Not yet recruiting | FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
15. | | Recruiting | PEG-Interferon alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer |
16. | | Recruiting | Carboplatin Plus Docetaxel and Paclitaxel in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
17. | | Recruiting | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Conditions: recurrent thyroid cancer; stage IV follicular thyroid cancer; stage IV papillary thyroid cancer |
18. | | Recruiting | FR901228 in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Conditions: gastrointestinal carcinoid tumor; Islet Cell Carcinoma; pulmonary carcinoid tumor |
19. | | Recruiting | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
20. | | Recruiting | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma |
21. | | Recruiting | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
22. | | Not yet recruiting | A Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Condition: Ovarian Cancer |
23. | | Not yet recruiting | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
24. | | Recruiting | CA-125 in Screening Patients at High Risk for Ovarian Cancer Condition: ovarian epithelial cancer |
25. | | Recruiting | The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients Condition: Thyroid Cancer |
26. | | Recruiting | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors Conditions: Breast Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Lung Neoplasms |
27. | | Recruiting | Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Condition: Zollinger-Ellison Syndrome |
28. | | Recruiting | Adjuvant Intraperitoneal Carboplatin With Paclitaxel in Treating Patients Who Had Initial Debulking Surgery for Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
29. | | Recruiting | TLK286 Compared With Either Liposomal Doxorubicin or Topotecan as Third-Line Therapy in Treating Patients With Platinum-Refractory or Platinum-Resistant Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
30. | | Recruiting | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors Conditions: adult solid tumor; Breast Cancer; Lung Cancer; neurotoxicity; ovarian epithelial cancer; Prostate Cancer |
31. | | Recruiting | Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer Condition: anaplastic thyroid cancer |
32. | | Recruiting | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Conditions: peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer |
33. | | Recruiting | Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
34. | | Recruiting | Oral Tyrosine Kinase Inhibitor of VEGFR-2 to Treat Recurrent or Persistent Small-volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer Condition: Ovarian Cancer |
35. | | Recruiting | BB-10901 in Treating Patients With Recurrent or Refractory Lung Cancer, Metastatic Carcinoid Tumor, or Other Solid Tumors Conditions: adult solid tumor; gastrointestinal carcinoid tumor; Neuroendocrine Carcinoma; Non-small cell lung cancer; pulmonary carcinoid tumor; ... |
36. | | Recruiting | Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease Conditions: Breast Cancer; Endocrine Cancer; female reproductive cancer; Graft Versus Host Disease; hematopoietic and lymphoid cancer; Neuroblastoma |
37. | | Recruiting | A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Condition: Ovarian Cancer |
38. | | Recruiting | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
39. | | Recruiting | Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer |
40. | | Recruiting | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Conditions: stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; ... |
41. | | Recruiting | Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors Conditions: extragonadal germ cell tumor; Testicular Cancer |
42. | | Recruiting | Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Condition: Adrenal Cortex Neoplasms |
43. | | Recruiting | Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors Conditions: adult brain tumor; extragonadal germ cell tumor; ovarian germ cell tumor; Testicular Cancer |
44. | | Recruiting | Tariquidar and Docetaxel to Treat Patients with Lung, Ovarian, and Cervical Cancer Conditions: Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms |
45. | | Recruiting | Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Conditions: stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer |
46. | | Recruiting | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Conditions: stage II ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer; ... |
47. | | Recruiting | Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors Conditions: childhood mature and immature teratomas; childhood extragonadal malignant germ cell tumor |
48. | | Recruiting | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; stage III ovarian epithelial cancer; ... |
49. | | Recruiting | Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Conditions: Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
50. | | Recruiting | Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Conditions: Endocrine Cancer; Gastrointestinal Cancer; Head and Neck Cancer; metastatic cancer |